Mining high-throughput screens for cancer drug targets-lessons from yeast chemical-genomic profiling and synthetic lethality

Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery

Volumn 2, Issue 3, 2012, Pages 263-272

  Heiskanen, Marja A ^a   Aittokallio, Tero ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DISEASES; GENES; MEDICAL APPLICATIONS; ONCOLOGY; YEAST;

CELLULAR TARGETS; DRUG-TARGET INTERACTIONS; FULL INFORMATIONS; HIGH DIMENSIONAL DATASETS; HIGH THROUGHPUT SCREENING; HIGH-THROUGHPUT SCREENS; STATE OF THE ART; THERAPEUTIC EFFICACY;

DATA MINING;

EID: 84873169591     PISSN: 19424787     EISSN: 19424795     Source Type: Journal    
DOI: 10.1002/widm.1055     Document Type: Article

References (46)

1. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4:682-690
2. Pe'er D,HacohenN. Principles and strategies for developing network models in cancer. Cell 2011, 144:864- 873
3. Kaelin W. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689-698
4. Iglehart JD, Silver DP. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 2009, 361:189-191
5. Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 2011, 585:1-6
6. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011, 21:34-41
7. WeissWA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 2007, 3:739-744
8. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, RothMGet al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819
9. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X,Hinkle G, Boehm JS, Beroukhim R, Weir BA et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008, 105:20380-20385
10. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O. Highthroughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009, 15:6070-6078
11. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. A genomewide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835- 848
12. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112
13. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006, 3:777-779
14. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064- 1068
15. Boone C, Bussey H, Andrews BJ. Exploring genetic interactions and networks with yeast. Nat Rev Genet 2007, 8:437-449
16. Sturgeon CM, Kemmer D, Anderson HJ, Roberge M. Yeast as a tool to uncover the cellular targets of drugs. Biotechnol J 2006, 1(3):289-298
17. Smith AM, Ammar R, Nislow C, Giaever G. A survey of yeast genomic assays for drug and target discovery. Pharmacol Ther 2010, 127:156-164
18. Ho CH, Piotrowski J, Dixon SJ, Baryshnikova A, Costanzo M, Boone C. Combining functional genomics and chemical biology to identify targets of bioactive compounds. Curr Opin Chem Biol 2011, 15:66-78
19. Costanzo M, Baryshnikova A, Myers CL, Andrews B, Boone C. Charting the genetic interactionmap of a cell. Curr Opin Biotechnol 2011, 22:66-74
20. Conde-Pueyo N, Munteanu A, Solé RV, Rodríguez-Caso C. Human synthetic lethal inference as potential anti-cancer target gene detection. BMC Syst Biol 2009, 3:116
21. McManus KJ, Barrett IJ, Nouhi Y, Hieter P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci USA 2009, 106:3276-3281
22. Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, Burke DJ, Theodorescu D. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 2011, 13:72-80
23. Tischler J, Lehner B, Fraser AG. Evolutionary plasticity of genetic interaction networks. Nat Genet 2008, 40:390-391
24. Lindén RO, Eronen VP, Aittokallio T. Quantitative maps of genetic interactions in yeast-comparative evaluation and integrative analysis. BMC Syst Biol 2011, 5:45
25. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999, 285:901-906
26. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S et al. The genetic landscape of a cell. Science 2010, 327:425-431
27. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, Lee W, Proctor M, St Onge RP, Tyers M, Koller D et al. The chemical genomic portrait of yeast:uncovering a phenotype for all genes. Science 2008, 320:362-365
28. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S, Lucau-Danila A, Anderson K, Andre B et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002, 418:387-391
29. Chan JNY, Nislow C, Emili A. Recent advances and method development for drug target identification. Trends Pharmacol Sci 2009, 31:82-88
30. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, Davis RW. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 1999, 21:278-283
31. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 2004, 22:62-69
32. Kapitzky L, Beltrao P, Berens TJ, Gassner N, Zhou C, Wüster A, Wu J, Babu MM, Elledge SJ, Toczyski D et al. Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. Mol Syst Biol 2010, 6:451
33. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jaramillo DF, Chu AM, Jordan MI, Arkin AP, Davis RW. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci USA 2004, 101:793-798
34. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004, 116:121-137
35. Lee W, St Onge RP, Proctor M, Flaherty P, Jordan MI, Arkin AP, Davis RW, Nislow C, Giaever G. Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet 2005, 1:e24
36. Hillenmeyer ME, Ericson E, Davis RW, Nislow C, Koller D, Giaever G. Systematic analysis of genomewide fitness data in yeast reveals novel gene function and drug action. Genome Biol 2010, 11:R30
37. Mani R, St Onge RP, Hartman JL, Giaver G, Roth FP. Defining genetic interaction. Proc Natl Acad Sci USA 2008, 105:3461-3466
38. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, Von Mering C, Jensen LJ, Beyer A, Bork P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 2010, 38:D552-D556
39. Reinke A, Anderson S, McCaffery JM, Yates J, Aronova S, Chu S, Fairclough S, Iverson C, Wedaman KP, Powers T. TORcomplex 1 includes a novel component, Tco89p (YPL180w), and cooperates with Ssd1p to maintain cellular integrity in Saccharomyces cerevisiae. J Biol Chem 2004, 279:14752-14762
40. Hoyt MA, Macke JP, Roberts BT, Geiser JR. Saccharomyces cerevisiae PAC2 functions with CIN1, 2 and 4 in a pathway leading to normal microtubule stability. Genetics 1997, 146:849-857
41. Chen RH, Brady DM, Smith D, Murray AW, Hardwick KG. The spindle checkpoint of budding yeast depends on a tight complex between theMad1 and Mad2 proteins.Mol Biol Cell 1999, 10:2607-2618
42. Flaherty P, Giaever G, Kumm J, Jordan MI, Arkin AP. A latent variable model for chemogenomic profiling. Bioinformatics 2005, 21:3286-3293
43. Han S, Kim D. Inference of protein complex activities from chemical-genetic profile and its applications: predicting drug-target pathways. PLoS Comput Biol 2008, 4:e1000162
44. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD et al. Functional discovery via a compendium of expression profiles. Cell 2000, 102:109- 126
45. Mattiazzi M, Curk T, Krizaj I, Zupan B, Petrovic U. Inference of the molecular mechanism of action from genetic interaction and gene expression data. OMICS Journal of Integrative Biology 2010, 14:357-367
46. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KNet al. The ConnectivityMap: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935